You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Deerfield Private Design Fund | 0 | 100,515 | 0 | 100,515 | 100,515 | 0.72% |
| Deerfield Special Situations Fund | 0 | 281,184 | 0 | 281,184 | 281,184 | 2.03% |
| Deerfield Private Design International | 0 | 161,788 | 0 | 161,788 | 161,788 | 1.17% |
| Deerfield Private Design Fund II | 0 | 181,560 | 0 | 181,560 | 181,560 | 1.31% |
| Deerfield Private Design International II | 0 | 208,053 | 0 | 208,053 | 208,053 | 1.50% |
| Deerfield Mgmt | 0 | 933,100 | 0 | 933,100 | 933,100 | 6.72% |
| Deerfield Management Company | 0 | 936,175 | 0 | 936,175 | 936,175 | 6.74% |
| James E. Flynn | 0 | 936,175 | 0 | 936,175 | 936,175 | 6.74% |
Page 1 of 15 – SEC Filing
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13D
[Rule 13d-101]
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §
21.16d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a)
(Amendment No. 3)*
Alpine
Immune Sciences, Inc.
(Name
of Issuer)
Common
Stock, par value $0.001 per share
(Title
of Class of Securities)
02083G100
(CUSIP
Number)
| David Clark Deerfield 780 Third New York, (212) 551-1600 With a Jonathan Mark Wood Katten 575 Madison New York, (212) 940-8800 |
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
July
24, 2017
(Date
of Event which Requires Filing of this Statement)
If the filing person
has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.
Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7
for other parties to whom copies are to be sent.
(Continued on following
pages)
(Page 1 of 15 Pages)
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 2 of 15 – SEC Filing
SCHEDULE 13D
| CUSIP No. 02083G100 | Page 2 of 15 Pages |
| 1 | NAME OF REPORTING PERSONS Deerfield Private Design Fund, L.P. | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☒ | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS WC | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT | ☐ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | |
| 8 | SHARED VOTING POWER 100,515 | ||
| 9 | SOLE DISPOSITIVE POWER 0 | ||
| 10 | SHARED DISPOSITIVE POWER 100,515 | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 100,515 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN | ☐ | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.72% | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 3 of 15 – SEC Filing
SCHEDULE 13D
| CUSIP No. 02083G100 | Page 3 of 15 Pages |
| 1 | NAME OF REPORTING PERSONS Deerfield Special | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☒ | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS WC | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT | ☐ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | |
| 8 | SHARED VOTING POWER 281,184 | ||
| 9 | SOLE DISPOSITIVE POWER 0 | ||
| 10 | SHARED DISPOSITIVE POWER 281,184 | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 281,184 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN | ☐ | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.03% | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 4 of 15 – SEC Filing
SCHEDULE 13D
| CUSIP No. 02083G100 | Page 4 of 15 Pages |
| 1 | NAME OF REPORTING PERSONS Deerfield Private Design International, L.P. | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☒ | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS WC | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT | ☐ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands | ||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | |
| 8 | SHARED VOTING POWER 161,788 | ||
| 9 | SOLE DISPOSITIVE POWER 0 | ||
| 10 | SHARED DISPOSITIVE POWER 161,788 | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 161,788 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN | ☐ | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 1.17% | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 5 of 15 – SEC Filing
SCHEDULE 13D
| CUSIP No. 02083G100 | Page 5 of 15 Pages |
| 1 | NAME OF REPORTING PERSONS Deerfield Private Design Fund II, L.P. | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☒ | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS WC | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT | ☐ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | |
| 8 | SHARED VOTING POWER 181,560 | ||
| 9 | SOLE DISPOSITIVE POWER 0 | ||
| 10 | SHARED DISPOSITIVE POWER 181,560 | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 181,560 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN | ☐ | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 1.31% | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 6 of 15 – SEC Filing
SCHEDULE 13D
| CUSIP No. 02083G100 | Page 6 of 15 Pages |
| 1 | NAME OF REPORTING PERSONS Deerfield Private Design International II, L.P. | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☒ | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS WC | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT | ☐ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands | ||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | |
| 8 | SHARED VOTING POWER 208,053 | ||
| 9 | SOLE DISPOSITIVE POWER 0 | ||
| 10 | SHARED DISPOSITIVE POWER 208,053 | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 208,053 | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN | ☐ | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 1.50% | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 7 of 15 – SEC Filing
SCHEDULE 13D
| CUSIP No. 02083G100 | Page 7 of 15 Pages |
| 1 | NAME OF REPORTING PERSONS Deerfield Mgmt, | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☒ | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS AF | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT | ☐ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | |
| 8 | SHARED VOTING POWER 933,100 (1) | ||
| 9 | SOLE DISPOSITIVE POWER 0 | ||
| 10 | SHARED DISPOSITIVE POWER 933,100 (1) | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 933,100 (1) | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN | ☐ | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.72% | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
(1) Comprised of 281,184 shares held by Deerfield Special Situations
Fund, L.P., 100,515 shares held by Deerfield Private Design Fund, L.P., 161,788 shares held by Deerfield Private Design International,
L.P., 181,560 shares held by Deerfield Private Design Fund II, L.P., and 208,053 shares held by Deerfield Private Design International
II, L.P.
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 8 of 15 – SEC Filing
SCHEDULE 13D
| CUSIP No. 02083G100 | Page 8 of 15 Pages |
| 1 | NAME OF REPORTING PERSONS Deerfield Management Company, L.P. | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☒ | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS AF | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT | ☐ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | |
| 8 | SHARED VOTING POWER 936,175 (2) | ||
| 9 | SOLE DISPOSITIVE POWER 0 | ||
| 10 | SHARED DISPOSITIVE POWER 936,175 (2) | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 936,175 (2) | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN | ☐ | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.74% | ||
| 14 | TYPE OF REPORTING PERSON PN | ||
(2) Comprised of 281,184 shares held by Deerfield Special Situations
Fund, L.P., 100,515 shares held by Deerfield Private Design Fund, L.P., 161,788 shares held by Deerfield Private Design International,
L.P., 181,560 shares held by Deerfield Private Design Fund II, L.P., 208,053 shares held by Deerfield Private Design International
II, L.P. and 3,075 shares of Common Stock underlying an option held by Howard P. Furst, a partner in Deerfield Management Company,
L.P. and a director of the Issuer.
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 9 of 15 – SEC Filing
SCHEDULE 13D
| CUSIP No. 02083G100 | Page 9 of 15 Pages |
| 1 | NAME OF REPORTING PERSONS James E. Flynn | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) ☐ (b) ☒ | |
| 3 | SEC USE ONLY | ||
| 4 | SOURCE OF FUNDS AF | ||
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT | ☐ | |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION United States of America | ||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 | |
| 8 | SHARED VOTING POWER 936,175 (3) | ||
| 9 | SOLE DISPOSITIVE POWER 0 | ||
| 10 | SHARED DISPOSITIVE POWER 936,175 (3) | ||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 936,175 (3) | ||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN | ☐ | |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.74% | ||
| 14 | TYPE OF REPORTING PERSON IN | ||
(3) Comprised of 281,184 shares held by Deerfield Special Situations
Fund, L.P., 100,515 shares held by Deerfield Private Design, L.P., 161,788 shares held by Deerfield Private Design International,
L.P., 181,560 shares held by Deerfield Private Design Fund II, L.P., 208,053 shares held by Deerfield Private Design International
II, L.P. and 3,075 shares of Common Stock underlying an option held by Howard P. Furst, a partner in Deerfield Management Company,
L.P. and a director of the Issuer.
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 10 of 15 – SEC Filing
This Amendment No. 3 (this “Amendment”)
to Schedule 13D amends the Schedule 13D filed on June 26, 2015 by (i) Deerfield Mgmt, L.P. (“Deerfield Mgmt”),
(ii) Deerfield Special Situations Fund, L.P. (“Deerfield Special Situations Fund”), (iii) Deerfield Management
Company, L.P. (“Deerfield Management”), (iv) Deerfield Private Design Fund, L.P. (“Deerfield Private
Design”), (v) Deerfield Private Design International, L.P. (“Deerfield Private Design International”),
(vi) Deerfield Private Design Fund II, L.P. (“Deerfield Private Design II”), (vii) Deerfield Private Design
International II, L.P. (“Deerfield Private Design International II”) and (viii) James E. Flynn, a natural person
(“Flynn” and collectively with Deerfield Mgmt, Deerfield Special Situations Fund, Deerfield Management, Deerfield
Private Design, Deerfield Private Design International, Deerfield Private Design II and Deerfield Private Design International
II, the “Reporting Persons”), with respect to the securities of Alpine Immune Sciences, Inc. (formerly, Nivalis
Therapeutics, Inc.) (the “Issuer”), as amended by Amendment Nos. 1 and 2 thereto, filed on September 20, 2016
and April 25, 2017, respectively (as amended, the “Schedule 13D”). Deerfield Special Situations Fund, Deerfield
Private Design, Deerfield Private Design International, Deerfield Private Design II and Deerfield Private Design International
II are collectively referred to herein as the “Funds.” The purpose of this Amendment is to report changes in
the number and percentage of shares of the Issuer’s common stock beneficially owned by the Reporting Persons as a result
of the business combination and 1-for-4 reverse stock split effected by the Issuer on July 24, 2017.
Capitalized terms used but not otherwise
defined herein shall have the meanings ascribed to them in the Scheduled 13D.
| Item 4. | Purpose of Transaction. |
Item 4 of the Schedule 13D is hereby
amended by adding the following:
As previously disclosed by the Issuer,
on July 24, 2017, the Issuer consummated the Merger contemplated by the Merger Agreement. In connection with, and prior to the
completion of, the Merger, the Company effected a 1-for-4 reverse stock split of the Common Stock. As a result of such reverse
stock split, the number of shares of Common Stock beneficially owned by the Reporting Persons was reduced and, as a result of the
issuance of additional shares of Common Stock in connection with the Merger, the percentage of the Issuer’s outstanding Common
Stock beneficially owned by the Reporting Persons was also reduced.
Item 5. Interest in Securities of the Issuer.
Items 5(a), (b) and (c) of the Schedule
13D are hereby amended and restated as follows:
| (1) | Deerfield Mgmt | ||
| Number of shares: | 933,100 (comprised of shares held by Deerfield Special Situations Fund, Deerfield Private Design, Deerfield Private Design International, Deerfield Private Design II and Deerfield Private Design International II) | ||
| Percentage of shares: 6.72% | |||
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 11 of 15 – SEC Filing
| (2) | Deerfield Management | ||
| Number of shares: | 936,175 (comprised of shares held by Deerfield Special Situations International, Deerfield Special Situations Fund, Deerfield Private Design, Deerfield Private Design International, Deerfield Private Design II and Deerfield Private Design International II and shares underlying the September 2016 Option) | ||
| Percentage of shares: 6.74% | |||
| (3) | Deerfield Special Situations Fund | ||
| Number of shares: 281,184 | |||
| Percentage of shares: 2.03% | |||
| (4) | Deerfield Private Design | ||
| Number of shares: 100,515 | |||
| Percentage of shares: 0.72% | |||
| (5) | Deerfield Private Design International | ||
| Number of Shares: 161,788 | |||
| Percentage of Shares: 1.17% | |||
| (6) | Deerfield Private Design II | ||
| Number of Shares: 181,560 | |||
| Percentage of Shares: 1.31% | |||
| (7) | Deerfield Private Design International II | ||
| Number of Shares: 208,053 | |||
| Percentage of Shares: 1.50% | |||
| (8) | Flynn | ||
| Number of shares: | 936,175 (comprised of shares held by Deerfield Special Situations Fund, Deerfield Private Design, Deerfield Private Design International, Deerfield Private Design II and Deerfield Private Design International II and shares underlying the September 2016 Option) | ||
| Percentage of shares: 6.74% | |||
| (b) | |||
| (1) | Deerfield Mgmt | ||
| Sole power to vote or direct the vote: 0 | |||
| Shared power to vote or direct the vote: 933,100 | |||
| Sole power to dispose or to direct the disposition: 0 | |||
| Shared power to dispose or direct the disposition: 933,100 | |||
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 12 of 15 – SEC Filing
| (2) | Deerfield Management | ||
| Sole power to vote or direct the vote: 0 | |||
| Shared power to vote or direct the vote: 936,175 | |||
| Sole power to dispose or to direct the disposition: 0 | |||
| Shared power to dispose or direct the disposition: 936,175 | |||
| (3) | Deerfield Special Situations Fund | ||
| Sole power to vote or direct the vote: 0 | |||
| Shared power to vote or direct the vote: 281,184 | |||
| Sole power to dispose or to direct the disposition: 0 | |||
| Shared power to dispose or direct the disposition: 281,184 | |||
| (4) | Deerfield Private Design | ||
| Sole power to vote or direct the vote: 0 | |||
| Shared power to vote or direct the vote: 100,515 | |||
| Sole power to dispose or to direct the disposition: 0 | |||
| Shared power to dispose or direct the disposition: 100,515 | |||
| (5) | Deerfield Private Design International | ||
| Sole power to vote or direct the vote: 0 | |||
| Shared power to vote or direct the vote: 161,788 | |||
| Sole power to dispose or to direct the disposition: 0 | |||
| Shared power to dispose or direct the disposition: 161,788 | |||
| (6) | Deerfield Private Design II | ||
| Sole power to vote or direct the vote: 0 | |||
| Shared power to vote or direct the vote: 181,560 | |||
| Sole power to dispose or to direct the disposition: 0 | |||
| Shared power to dispose or direct the disposition: 181,560 | |||
| (7) | Deerfield Private Design International II | ||
| Sole power to vote or direct the vote: 0 | |||
| Shared power to vote or direct the vote: 208,053 | |||
| Sole power to dispose or to direct the disposition: 0 | |||
| Shared power to dispose or direct the disposition: 208,053 | |||
| (8) | Flynn | ||
| Sole power to vote or direct the vote: 0 | |||
| Shared power to vote or direct the vote: 936,175 | |||
| Sole power to dispose or to direct the disposition: 0 | |||
| Shared power to dispose or direct the disposition: 936,175 | |||
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 13 of 15 – SEC Filing
Flynn is the sole member of the general
partner of each of Deerfield Mgmt and Deerfield Management. Deerfield Mgmt is the general partner, and Deerfield Management is
the investment advisor, of Deerfield Special Situations Fund, Deerfield Private Design, Deerfield Private Design International,
Deerfield Private Design II and Deerfield Private Design International II. Pursuant to an arrangement between Deerfield Management
and Furst, for so long as Furst is employed by Deerfield Management, any compensation that Furst receives from the Issuer is for
the economic benefit of Deerfield Management and must be transferred to Deerfield Management, for no consideration, subject to
applicable restrictions on transfer. See Item 6 for additional information regarding such arrangement.
(c) No Reporting Person has effected any
transactions in the Common Stock during the past 60 days.
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 14 of 15 – SEC Filing
SIGNATURE
After reasonable inquiry
and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true,
complete and correct.
Dated: July 28, 2017
| DEERFIELD MGMT, L.P. By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Name: Jonathan Title: Attorney-in-Fact DEERFIELD SPECIAL SITUATIONS FUND, L.P. By: Deerfield Mgmt, By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Name: Jonathan Title: Attorney-in-Fact DEERFIELD PRIVATE DESIGN FUND, L.P. By: Deerfield Mgmt, By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Name: Jonathan Title: Attorney-in-Fact DEERFIELD PRIVATE DESIGN INTERNATIONAL, L.P. By: Deerfield Mgmt, By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Name: Jonathan Title: Attorney-in-Fact |
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)
Page 15 of 15 – SEC Filing
| DEERFIELD PRIVATE DESIGN FUND II, L.P. By: Deerfield Mgmt, By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Name: Jonathan Title: Attorney-in-Fact DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P. By: Deerfield Mgmt, By: J.E. Flynn Capital, LLC, General Partner By: /s/ Jonathan Name: Jonathan Title: Attorney-in-Fact DEERFIELD MANAGEMENT COMPANY, L.P. By: Flynn Management LLC, General Partner By: /s/ Jonathan Name: Jonathan Title: Attorney-in-Fact JAMES E. FLYNN /s/ Jonathan Jonathan Isler, Attorney-in-Fact |
